Pharmacological Management of Tuberculosis, Challenges, and Potential Strategies
Authors:
- Bernadette Xin Jie TuneBTBernadette Xin Jie Tune
- Neeraj Kumar FuloriaNFNeeraj Kumar Fuloria
- Yuan Seng WuYWYuan Seng Wu
Open Access
- 9 February 2024
- Vol. 7 (1)
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Lipid nanoparticles with improved biopharmaceutical attributes for tuberculosis treatmentInternational Journal of Pharmaceutics, 2021
- Linezolid for drug-resistant pulmonary tuberculosisCochrane Database of Systematic Reviews, 2019
- Isoniazid-Rifapentine for Latent Tuberculosis Infection: A Systematic Review and Meta-analysisAmerican Journal of Preventive Medicine, 2018
- Fluoroquinolone derivatives and their anti-tubercular activitiesEuropean Journal of Medicinal Chemistry, 2018
- Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosisBiomedicine & Pharmacotherapy, 2017
- Optimizing the clinical pharmacology of tuberculosis medicationsClinical Pharmacology & Therapeutics, 2015
- Directly observed therapy for treating tuberculosisCochrane Database of Systematic Reviews, 2015
- Present epidemiology of tuberculosis. Prevention and control programsEnfermedades Infecciosas y Microbiología Clínica, 2011
- New anti-tuberculosis drugs in clinical trials with novel mechanisms of actionDrug Discovery Today, 2008
- Multicenter evaluation of reverse line blot assay for detection of drug resistance in Mycobacterium tuberculosis clinical isolatesJournal of Microbiological Methods, 2004